"Take it to PMs... that’s what they’re for"
So
"Take it to PMs... that’s what they’re for"
So that's where opposing opinions are supposed to go according to you? Just curious - what is your medical background and your experience with prescribing patients with this "quack science"? I'm only asking because you're attacking someone who has this experience and speaks from knowledge that was gained by treating patients with what you're labeling as "quack science". So, please enlighten us as to your background and first-hand experience.
And just a piece of advice even though you didn't ask for it but clearly need it, know your audience before you starting giving "advice" to others on this board.
1
CytoDyn Inc (CYDY) Stock Research Links
My comments are just my opinions and should NOT be taken as investment advice.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
American demand has put a cork in the easy story, and Italian wine producers cannot pretend otherwise. In the first nine months of 2026, U.S. imports of Italian wine dropped 18.4% by value. That is painful because the United States remains Italy's largest destination market by value, not some side shelf that can be ignored until conditions improve. Still, the broader U.S....
Continue Reading
A six-month regulatory sprint is the sort of result that makes a crowded diagnostics field pause and squint. DNV has issued an IVDR certificate to FAMID Biomedical Technology for its E7 Oncoprotein Rapid Test Kit, a Class C in vitro diagnostic intended to aid diagnosis of cervical epithelial cell lesions through detection of HPV E7 oncoprotein in cervical cell samples....
Continue Reading
A twenty-share pile of INVZ is about to become one share, and nobody should confuse that paperwork with a turnaround. Innoviz plans to enact a 1-for-20 reverse split at 11:59 p.m. Eastern on Friday, December 4, with split-adjusted trading expected when Nasdaq opens on December 7. This is a blunt instrument aimed at one immediate problem: getting the quoted share price...
Continue Reading
A missed postpartum appointment can look like a small administrative failure until it is not. Fidelis Care’s $140,000 round of Here for Your Health maternal health grants is aimed squarely at that unglamorous but consequential gap: keeping new mothers connected to care after delivery, particularly in underserved New York communities. Small Dollars, Very Specific...
Continue Reading
A lap record, a camera crew, and five straight trophies make a louder statement than another glossy corporate slogan. Hagerty won Best Journalism Film at the 2026 International Motor Film Awards on Nov. 14, held at the Petersen Automotive Museum in Los Angeles. The company has taken that particular award home five years running, powered again by Jason Cammisa and his...
Continue Reading
Four million worked hours without a lost-time accident is the sort of number that ought to make people pause, especially in poultry processing. Mar-Jac Poultry’s Gainesville facility earned Workplace Safety recognition from the Greater Hall Chamber of Commerce after reaching that mark, and this is one corporate achievement that deserves a little less eye-rolling than...
Continue Reading
A missile program lives or dies on unglamorous hardware, and solid rocket motors are about as unglamorous as it gets until somebody cannot build enough of them. Raytheon has awarded Ursa Major and Avio USA a joint contract to develop solid rocket motors for the U.S. Navy’s Tactical Tomahawk missile program. That is the whole headline, and it matters more than the thin...
Continue Reading
A passcard, a hidden door, and 12,000 square feet of mischief have landed at Somernova. Edge of Elsewhere, the new flagship attraction from Boston-area creative studio Midnight Mansion, is open in Somerville’s Union Square as of November 18, 2026. It is part interactive art installation, part puzzle game, part physical story world. That sounds delightfully odd, which is...
Continue Reading
A refinery giant talking about green jet fuel at a climate summit is exactly the sort of thing that makes old energy hands squint first—and then check the asset list. Sinopec did bring more than lofty language to its Nov. 16 COP31 side event in Antalya: it brought long-range energy forecasts, named fuel-production routes, hydrogen infrastructure and operating projects....
Continue Reading
Pain care gets muddled the minute people assume every ache needs the same doorway. Dr. Mala Young, a physical medicine and rehabilitation expert in Ann Arbor, Michigan, makes a useful distinction: a physiatrist and an orthopedic doctor may both see pain, mobility trouble, and injury, but they are not interchangeable. That sounds obvious until someone is staring at back...
Continue Reading
Top 5 Most Recently Viewed Articles
Wage Trends in Childcare: A New Era Unfolds The landscape of childcare in America is morphing before our eyes, driven by economic forces and a changing workforce. With Crunch Care releasing its 2026 Childcare Salary Guide, we’re finally getting a clear picture of where wages and demand are headed, and it’s anything but static. Charting the Course of Childcare Wages...
Continue Reading
Sapiens International Corporation Announces Q1 2025 Financial Results Sapiens International Corporation (NASDAQ: SPNS) operates as a leading provider of software solutions specifically designed for the insurance sector. The company is preparing to unveil its financial outcomes for the first quarter of 2025. This significant announcement is scheduled for a date in early...
Continue Reading
Maison Law Launches Innovative Mobility Training Facility The "Maison Law Mobility Training Course at Kaweah Health" is a groundbreaking initiative that significantly improves the rehab journey for patients. This unique facility, the first of its kind in the area, is aimed at providing essential resources that empower patients to overcome their rehabilitation challenges...
Continue Reading
Aarki Unveils Encore: Revolutionizing Mobile Marketing Growth Encore is a groundbreaking platform that unifies User Acquisition and Retargeting through advanced machine learning, catering to the needs of mobile marketers grappling with strict privacy norms. By enhancing performance on both iOS and Android, Encore leverages deep neural network optimization to foster...
Continue Reading
Promising Phase 2 Trial Results for BX211 BiomX Inc. (NYSE American: PHGE), a pioneering clinical-stage company, recently revealed impressive topline results from its Phase 2 trial examining BX211 for diabetic foot osteomyelitis (DFO). This trial focused on individuals suffering from infections linked to Staphylococcus aureus, a bacteria known to complicate diabetic...
Continue Reading